Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Ellin Berman et al.|Blood|2020Cited by 318
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A. Eyre, Graham P. Collins, Harriet S. Walter et al.|Haematologica|2018Cited by 137
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E. Roeker, Anthony R. Mato, Peter Dreger et al.|Blood Advances|2020Cited by 86
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70